EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

EYPT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $72.15M rose 23.2% year over year, behind the +45.4% change in trailing-twelve-month research & development. Sequentially, it rose 21.8% from the prior quarter. Over 3 fiscal years it compounded at +64.5% a year.

Context

  • Research & development amounted to 704.6% of revenue in FY2025, up 397.4 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +23.2% toward the trailing-twelve-month pace of +45.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$72.15M+21.8% QoQ
Last fiscal yearDec 2025
$221.04M+66.3% YoY
LTMMar 2026
$234.61M+45.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.2%——
1 year+66.3%——
3-year CAGR+64.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
221.04M USD
Year-over-year change
+66.3%
4-year CAGR
+66.9%

Research & Development vs competitors

How EYPT compares with its peers on the latest reported figures

  • EYPT's LTM Mar 2026 research & development of $234.61M is the 3rd highest of the 11 companies compared; the peer median is $142.57M.
  • Its year-over-year change of +45.4% is the 2nd highest of 11, against a peer median of +12.3%.
  • Research & development amounts to 3080.9% of revenue for EYPT, versus a peer median of 363.4%.
EYPT Competitors Peer median
Research & Development for EYPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
KURAKura Oncology, Inc.LTM Mar 2026$260.36M +37.3%+39.3%363.4%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$234.61M +45.4%+64.5%3080.9%
KODKodiak Sciences Inc.LTM Sep 2026$208.43M +23.6%-12.0%—
PRMEPrime Medicine, Inc.LTM Mar 2026$154.18M -2.5%+22.8%3822.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M +14.3%+7.7%—
SEPNSepterna, Inc.LTM Sep 2026$132.66M +56.0%—137.8%
PROKProKidney Corp.LTM Mar 2026$120.7M -5.5%+11.6%13577.3%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$111.11M +29.3%+58.7%—
SVRASavara Inc.LTM Mar 2026$85.64M +6.5%+42.9%—
RZLTRezolute, Inc.LTM Mar 2026$59.77M +0.0%+23.7%—
Peer median (excluding EYPT) $142.57M+12.3%+22.8%363.4%

Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.94M41.4M46.02M43.27M31.37M
Cost of Revenue8.18M8.33M4.63M3.71M2.07M
Gross Profit28.76M33.08M41.39M39.56M29.31M
Gross Margin77.9%79.9%89.9%91.4%93.4%
Research & Development28.5M49.64M64.66M132.93M221.04M
Selling, General & Admin53.08M60.32M51.79M52.49M51.7M
Operating Expenses84.04M132.72M116.45M185.42M272.74M
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
EBITDA(50.15M)(96.62M)(69M)(129.23M)(229.34M)
EBITDA Margin-135.8%-233.4%-149.9%-298.6%-731.1%
Operating Income(55.28M)(99.64M)(75.07M)(145.85M)(243.43M)
Operating Margin-149.6%-240.6%-163.1%-337.1%-776.0%
Interest Income292K2.13M6.95M15.09M11.75M
Interest Expense5.5M3.19M1.25M14K(33K)
Other Income / Expenses(3.14M)(2.62M)4.36M15.07M11.75M
Income Before Tax(58.42M)(102.25M)(70.71M)(130.78M)(231.68M)
Pre-Tax Margin-158.1%-247.0%-153.7%-302.2%-738.5%
Income Tax Expense0083K90K279K
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Net Margin-158.1%-247.0%-153.8%-302.4%-739.4%
EPS (Basic)(2.03)(2.74)(1.82)(2.32)(3.17)
EPS (Diluted)(2.03)(2.74)(1.82)(2.32)(3.17)
Weighted Avg Shares28.76M37.32M38.9M56.3M73.25M
Weighted Avg Shares (Diluted)28.76M37.32M38.9M56.3M73.25M

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Intrinsic Alpha fair value

Locked

Current Price

$2.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.